First-hits in the multi-hit process of leukemogenesis originate in germline or hematopoietic stem cells (HSCs), yet leukemiainitiating cells (LICs) usually have a lineage-committed phenotype. The molecular mechanisms underlying this compartment shift during leukemia evolution have not been a major focus of investigation and remain poorly understood. Here a mechanism underlying this shift was examined in the context of Runx1 deficiency, a frequent leukemia-initiating event. Lineage-negative cells isolated from the bone marrow of Runx1-haploinsufficient and wild-type control mice were cultured in granulocyte-colonystimulating factor to force lineage commitment. Runx1-haploinsufficient cells demonstrated significantly greater and persistent exponential cell growth than wild-type controls. Not surprisingly, the Runx1-haploinsufficient cells were differentiation-impaired, by morphology and by flow-cytometric evaluation for granulocyte differentiation markers. Interestingly, however, this impaired differentiation was not because of decreased granulocyte lineage commitment, as RNA and protein upregulation of the master granulocyte lineage-commitment transcription factor Cebpa, and Hoxb4 repression, was similar in wild-type and Runx1-haploinsufficient cells. Instead, RNA and protein expression of Cebpe, a key driver of progressive maturation after lineage commitment, were significantly decreased in Runx1-haploinsufficient cells. Primary acute myeloid leukemia cells with normal cytogenetics and RUNX1 mutation also demonstrated this phenotype of very high CEBPA mRNA expression but paradoxically low expression of CEBPE, a CEBPA target gene. Chromatin-immunoprecipitation analyses suggested a molecular mechanism for this phenotype: in wild-type cells, Runx1 binding was substantially greater at the Cebpe than at the Cebpa enhancer. Furthermore, Runx1 deficiency substantially diminished high-level Runx1 binding at the Cebpe enhancer, but lower-level binding at the Cebpa enhancer was relatively preserved. Thus, Runx1-deficiency permits Cebpa upregulation and the exponential cell growth that accompanies lineage commitment, but by impairing activation of Cebpe, a key proliferation-terminating maturation gene, extends this exponential growth. These mechanisms facilitate germline cell or HSC of origin, yet evolution into LIC with lineage-committed phenotype.
INTRODUCTION
Known first-hits in the multi-hit process of leukemogenesis are inactivating or dominant-negative mutations in RUNX1.
1 These first-hits originate in the germline in familial acute myeloid leukemia (AML, reviewed in the study by Owen et al. 2 ) and in hematopoietic stem cells (HSCs) in acquired AML. [3] [4] [5] Germline or stem cell origin of the first hit is necessary as these cells live long enough that there is a feasible possibility of secondary genetic abnormalities (additional hits) that can cooperate for evolution into AML. However, some of these secondary genetic abnormalities occur in daughter cells with restricted lineage potential. This is evident in familial AML, in which neoplastic evolution does not occur in the germline cells of origin, but is also true of acquired AML: self-renewing AML cells, also known as leukemia-initiating cells (LICs) or leukemia stem cells, have a lineage-committed phenotype by numerous surface markers (CD34 þ 38 þ , CLL-1 þ , CD71 þ , CD90 À , c-Kit-), [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] by strikingly high expression of lineage-specifying transcription factors such as CEBPA, PU.1/SPI1 or GATA1, [17] [18] [19] by inactivation of polycomb repressor complex 2 components that usually suppress lineage programs, 20 and by the observation that highly recurrent secondary genetic abnormalities such as FLT3 mutation are not detected in the HSC compartment. 5 Thus, a first-hit is present or originates in HSC, but creates conditions that favor further neoplastic evolution not necessarily in the HSC compartment itself but in lineage-committed progenitors. The molecular mechanisms underlying this compartment shift during leukemia evolution have not been a major focus of investigation and are poorly understood. A better understanding of these mechanisms could provide guidance for novel 1 treatments that exploit the lineage-committed cellular context of LIC to thereby spare uncommitted normal HSC.
RESULTS AND DISCUSSION
To investigate a basis for compartment shifts during evolution of myeloid cancers, lineage-negative HSC from wild-type and Runx1 haploinsufficient mice 21 were cultured in granulocyte-colonystimulating factor (G-CSF) to force lineage commitment. The Runx1-haploinsufficient cells demonstrated more rapid and persistent proliferation than wild-type controls (Figure 1a ). This growth advantage was also apparent in semi-solid media supplemented with G-CSF: Runx1-haploinsufficient cells produced a higher number and larger-sized colonies than wild-type control (Figure 1b) . The Runx1-haploinsufficient cells were differentiationimpaired: after 15 days of culture, Runx1-haploinsufficient cells included mitotic figures and immature forms with high nuclearcytoplasmic ratios and decreased neutrophilic granulation, whereas wild-type cells demonstrated mostly mature granulocytes ( Figure 1c) . Furthermore, the granulocyte-lineage markers Ly6G and CD11b were upregulated to a much lesser extent in Runx1-haploinsufficient cells than in wild-type controls (Figure 1d ).
To better understand the molecular mechanisms underlying the persistent proliferation and impaired differentiation, expression patterns of key hematopoietic transcription factors that determine lineage commitment and progressive maturation were examined. These were Hoxb4 that promotes self-renewal by HSC, Cebpa that drives granulocyte lineage commitment, and Cebpe that drives Figure 1 . Runx1-haploinsufficient cells are able to lineage commit but have impaired subsequent maturation. Lineage-negative (Lin À ) cells were isolated from bone marrow of Runx1 þ / À (haploinsufficient) and wild-type (WT) C57BL/6 mice using MACS Lineage Cell Depletion Kit (#130-090-858, Miltenyi Biotec Inc., Auburn, CA, USA). (a) Cell counts. Cytokine supplementation: 10 ng/ml of mSCF and 100 ng/ml of thrombopoietin (nondifferentiation promoting conditions) or 10 ng/ml of murine stem cell factor, 10 ng/ml of mIL-6 and G-CSF 20 ng/ml (PeproTech Inc., Rocky Hill, NJ, USA). Cell numbers were determined by automated cell counter every 3 days during 60 days of culture. Mean±standard deviation. Experiments performed in triplicate. (b) Colony formation by Runx1 þ / À and WT Lin À cells in semi-solid media. 2 Â 10 late granulocyte maturation and terminates proliferation. [22] [23] [24] [25] [26] [27] Repression of Hoxb4 and activation of Cebpa by G-CSF was similar in wild-type and Runx1-haploinsufficient cells (Figure 2a) . Despite the upregulation of Cebpa, Cebpe activation was significantly decreased in the Runx1-haploinsufficient cells, even after 15 days of culture with G-CSF (Figure 2a ). These observations were recapitulated at the protein level (Figure 2b ). This pattern of gene expression is also a characteristic of primary AML cells with mutated RUNX1 and normal cytogenetics: CEBPA was on average 430-fold more expressed than CEBPE and 46-fold more expressed than HOXB4 (Figure 2c ). Chromatin-immunoprecipitation analysis showed a basis for differential Cebpa and Cebpe activation in Runx1-deficient cells: in wild-type cells, Runx1 binding was substantially greater at the Cebpe than at the Cebpa enhancer 28, 29 (Figure 2d ). Furthermore, Runx1-deficiency substantially diminished high level Runx1 binding at the Cebpe enhancer, Enhancers of Cebpa and Cebpe were identified by others using ChIP coupled with deep sequencing. 28 ChIP performed using ChIP Assay Kit (cat#17-295, EMD Millipore, Billerica, MA, USA). 5 Â 10 6 cells bone marrow (BM) cells from WT and Runx1 þ /1 fresh BM cells were resuspended in 10 ml of media and formaldehyde was added to a final concentration of 1% followed by 10 min incubation at 37 1C. The media containing formaldehyde was removed and the cells were washed twice with ice-cold PBS containing protease inhibitor (cat#P8340, SigmaAldrich) and phosphatase inhibitor cocktails (cat#P0044, Sigma-Aldrich). Crosslinked cells were resuspended in SDS lysis buffer (Millipore, #20-163) and incubated for 10 min on ice. These cell pellets were sonicated at 15 s pulses with 45 s hold on ice for a total of 10 min of pulsing at full power (Fisher-Scientific Model #550 Sonic Dismembrator equipped with a microtip probe). Genomic DNA fragments of 200-bp and 1-kb in size were obtained (confirmed by agarose gel electrophoresis). After centrifugation at 4 1C, the supernatant was pre-cleared with salmon sperm DNA/Protein A agarose-50% slurry (Millipore, #16-157) for 30 min at 4 1C with agitation. A 10% aliquot (vol) of the precleared protein/ DNA mixture was removed and used for subsequent reverse transcription-PCR input quantification. 10 mg of anti-Runx1 ChIP grade antibody (cat#ab23980, Abcam, Cambridge, MA, USA) was added to the remaining protein/DNA mixture and incubated at 4 1C overnight with rotation. Salmon sperm DNA/Protein A agarose-50% slurry was added and incubated for 1 h at 4 1C followed by washes with the ChIP assay kit provided buffers. The immunoprecipitated (IP) complexes were reverse crosslinked at 65 1C for 4 h and DNA was recovered by phenol/ chloroform extraction protocol (Sigma). The IP products were amplified and quantified using real-time PCR. ChIP primer sequences are: (Figure 2d) . In other words, RUNX1 is more abundant at, and presumably more important, for regulating the Cebpe enhancer than the Cebpa enhancer.
Consistent with the present results, Runx1-haploinsufficient mice have decreased HSC but increased myeloid progenitors compared with wild-type controls. 21 Similarly, a murine knock-in model of point-mutated Runx1 demonstrated unaltered HSC emergence but defects in multiple committed hematopoietic lineages, and hematopoietic cells containing the leukemia fusion protein RUNX1-ETO demonstrated delayed granulocytic differentiation. 30, 31 Previously, we demonstrated that even CD34 þ 38 À subsets of primary AML cells demonstrate this pattern of very high CEBPA but relatively low HOXB4 and CEBPE expression compared with normal hematopoietic precursors, promyelocytes and neutrophils. 18, 32, 33 Ideally, leukemia treatments would suppress malignant clones but preserve normal HSC needed to restore blood counts. High expression of key transcription factors that drive differentiation (for example, CEBPA, PU.1) could be a difference between LIC and normal HSC that facilitates this goal, especially since the proliferationterminating differentiation genes usually activated by these transcription factors, although aberrantly suppressed in leukemia cells (for example, CEBPE), are genetically intact and thus in theory available for activation. For example, high baseline CEBPA expression explains rapid restoration of CEBPE expression and cycle exit by maturation of primary AML cells treated with corepressor antagonizing drugs (for example, decitabine) or with FLT3 inhibitors. 34 The same treatments preserve self-renewal of uncommitted normal HSC that do not express high levels of lineage-specifying transcription factors at baseline. [35] [36] [37] 
